Intermune Regulatory Approvals
It looks like Roche’s (Ticker: RHHBY) acquisition of Intermune (Ticker: ITMN) has a good chance of being completed by the end of this month if all the regulatory approvals are received. The company has to obtain approvals from three countries. The required approvals and decisions are as follows: US HSR 09/17, Australia 09/22 and Germany 09/25. This tender expires on 09/26, the day after the receipt of the last regulatory approval. The spread is not wide enough to play via common so I’ve been selling the January 2016 $70 Puts.